Topline results from open-label safety study (NORSE THREE) on target for Q2 2021 MONMOUTH JUNCTION, N.J. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of

Overallotment option on recent public offering partially exercised by underwriter Closed concurrent private placement for $3.0 million gross proceeds Aggregate gross proceeds of $41.6 million strengthens financial position and provides strategic optionality to maximize stockholder value MONMOUTH

MONMOUTH JUNCTION, N.J. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today

MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications,

MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today

Leading retina clinician Dr. Rahhal discusses the market need for an FDA-approved ophthalmic bevacizumab for treating wet AMD and other retinal diseases Terry Dagnon , COO, and Jeff Evanson , CCO, of Outlook Therapeutics share the clinical rationale and regulatory framework for developing ONS-5010

MONMOUTH JUNCTION, N.J. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence

All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021 MONMOUTH

MONMOUTH JUNCTION, N.J. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today that it has received

Advisory Co uncil to collaborate on ou t reach to retinal clinicians to support development and commercialization of ONS-5010, an investigational ophthalmic formulation of bevac i zumab MONMOUTH JUNCTION, N.J. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.